The new frontier of newborn screening: integrating genomics, metabolomics, and data science for inborn errors of metabolism
- 1Maternal and Children’s Health Research Institute, Shunde Women and Children’s Hospital, Guangdong Medical University
- 2Department of Pediatrics, Shunde Women and Children Hospital, Guangdong Medical University
Abstract
Newborn screening (NBS) for inborn errors of metabolism (IEMs) represents one of the most successful public health initiatives of the past century. Originating with the simple bacterial inhibition assay for phenylketonuria, the field was revolutionized by tandem mass spectrometry (MS/MS). Today, we stand at the precipice of a second, more profound revolution driven by the convergence of high-throughput genomics, next-generation metabolomics, and advanced data science. This review articulates this paradigm shift, detailing how MS/MS is being augmented by targeted DNA analysis and how whole genome sequencing and untargeted metabolomics, integrated with artificial intelligence, are expanding the detectable universe of disorders and enabling precision interventions. However, this powerful multi-omic approach raises critical challenges: incomplete penetrance, overdiagnosis, economic burden, psychosocial impacts, algorithm biases, and the genomic data gap that exacerbates health disparities. We critically examine the practical limitations of AI, the lack of evidence for cost-effectiveness, the slow pace of database updates, and the need for short-term reanalysis systems to “rescue” cases left undiagnosed. Global policy variations and data-sharing governance frameworks are also addressed. We conclude that the future of NBS lies not in sequential technology replacement, but in the responsible creation of a sophisticated, multi-omic biomedical information system to transform NBS into a foundational pillar of precision pediatric medicine. Graphical Abstract
Related
- A multimodal precision oncology platform integrating genomics,single-cell transcriptomics, and functional drug screening expandstherapeutic options in pediatric brain tumors
- Exercise oncology and tumor sterol metabolism: An emerging mechanistic frontier
- Genomics and metabolomics analyses reveal the endophytic fungus Neocucurbitaria sp. VM-36 as a potential source of bioactive metabolites against methicillin-resistant Staphylococcus aureus
- Nanomaterials Reshaping Tumor Metabolism: A New Frontier to Overcome T Cell Exhaustion.
- Metabolic Profiling, Antioxidant Activity, and Mechanistic Insights of Chicory from Northern and Southern China: Integrating Metabolomics, Machine Learning, Molecular Docking, Molecular Dynamics Simulations, and In Vitro Assays
BibTeX
@article{wasim2026frontier,
title = {{The new frontier of newborn screening: integrating genomics, metabolomics, and data science for inborn errors of metabolism}},
author = {Muhammad Wasim and Yajun Wang and Guoda Ma},
journal = {Orphanet Journal of Rare Diseases},
year = {2026},
month = jul,
doi = {10.1186/s13023-026-04513-0},
url = {https://doi.org/10.1186/s13023-026-04513-0},
note = {CC BY},
}
RIS
TY - JOUR
TI - The new frontier of newborn screening: integrating genomics, metabolomics, and data science for inborn errors of metabolism
AU - Muhammad Wasim
AU - Yajun Wang
AU - Guoda Ma
PY - 2026
DA - 2026/07/01
JO - Orphanet Journal of Rare Diseases
DO - 10.1186/s13023-026-04513-0
UR - https://doi.org/10.1186/s13023-026-04513-0
AB - Newborn screening (NBS) for inborn errors of metabolism (IEMs) represents one of the most successful public health initiatives of the past century. Originating with the simple bacterial inhibition assay for phenylketonuria, the field was revolutionized by tandem mass spectrometry (MS/MS). Today, we stand at the precipice of a second, more profound revolution driven by the convergence of high-throughput genomics, next-generation metabolomics, and advanced data science. This review articulates this paradigm shift, detailing how MS/MS is being augmented by targeted DNA analysis and how whole genome sequencing and untargeted metabolomics, integrated with artificial intelligence, are expanding the detectable universe of disorders and enabling precision interventions. However, this powerful multi-omic approach raises critical challenges: incomplete penetrance, overdiagnosis, economic burden, psychosocial impacts, algorithm biases, and the genomic data gap that exacerbates health disparities. We critically examine the practical limitations of AI, the lack of evidence for cost-effectiveness, the slow pace of database updates, and the need for short-term reanalysis systems to “rescue” cases left undiagnosed. Global policy variations and data-sharing governance frameworks are also addressed. We conclude that the future of NBS lies not in sequential technology replacement, but in the responsible creation of a sophisticated, multi-omic biomedical information system to transform NBS into a foundational pillar of precision pediatric medicine. Graphical Abstract
SN - 1750-1172
ER -